|
1
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J
Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S and
Horwich A; ESMO Guidelines Committee. Electronic address, :
Clinicalguidelines@esmo.org: Renal cell carcinoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:706–720. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russo P: Delayed systemic treatment in
metastatic renal-cell carcinoma. Lancet Oncol. 17:1187–1189. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farhood B, Najafi M and Mortezaee K:
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A
review. J Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaartinen T, Luostarinen A, Maliniemi P,
Keto J, Arvas M, Belt H, Koponen J, Mäkinen PI, Loskog A, Mustjoki
S, et al: Low interleukin-2 concentration favors generation of
early memory T cells over effector phenotypes during chimeric
antigen receptor T-cell expansion. Cytotherapy. 19:689–702. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Louis CU, Savoldo B, Dotti G, Pule M, Yvon
E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor
activity and long-term fate of chimeric antigen receptor-positive T
cells in patients with neuroblastoma. Blood. 118:6050–6056. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gattinoni L, Klebanoff CA, Palmer DC,
Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR,
Rosenberg SA and Restifo NP: Acquisition of full effector function
in vitro paradoxically impairs the in vivo antitumor efficacy of
adoptively transferred CD8+ T cells. J Clin Invest. 115:1616–1626.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janssen EM, Lemmens EE, Wolfe T, Christen
U, von Herrath MG and Schoenberger SP: CD4+ T cells are required
for secondary expansion and memory in CD8+ T lymphocytes. Nature.
421:852–856. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ho PC, Meeth KM, Tsui YC, Srivastava B,
Bosenberg MW and Kaech SM: Immune-based antitumor effects of BRAF
inhibitors rely on signaling by CD40L and IFNү. Cancer Res.
74:3205–3217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bos R and Sherman LA: CD4+ T-cell help in
the tumor milieu is required for recruitment and cytolytic function
of CD8+ T lymphocytes. Cancer Res. 70:8368–8377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukushima K and Yamashita K: Interleukin-2
carbohydrate recognition modulates CTLL-2 cell proliferation. J
Biol Chem. 276:7351–7356. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou XL, Wang WW, Zhu WG, Yu CH, Tao GZ,
Wu QQ, Song YQ, Pan P and Tong YS: High expression of long
non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor
prognosis in patients with esophageal squamous cell carcinoma
treated with definitive chemoradiotherapy. Mol Carcinog.
55:2095–2105. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
So B, Marcu L, Olver I, Gowda R and Bezak
E: Oesophageal cancer: Which treatment is the easiest to swallow? A
review of combined modality treatments for resectable carcinomas.
Crit Rev Oncol Hematol. 113:135–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han SZ, Liu HX, Yang LQ, Cui LD and Xu Y:
Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical
cancer through suppressing Bcl-2 signaling pathway via inactivating
STAT3/NF-KB. Biomed Pharmacother. 96:1403–1410. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan XY: Comparison of the cytotoxic effect
of fresh garlic, diallyl trisulfide, 5-fluorouracil (5-FU),
mitomycin C (MMC) and Cis-DDP on two lines of gastric cancer cells.
Zhonghua Zhong Liu Za Zhi. 7:103–105. 1985.(In Chinese). PubMed/NCBI
|
|
17
|
Hu X, Ma J, Vikash V, Li J, Wu D, Liu Y,
Zhang J and Dong W: Thymoquinone augments cisplatin-induced
apoptosis on esophageal carcinoma through mitigating the activation
of JAK2/STAT3 Pathway. Dig Dis Sci. 63:126–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gomyo Y, Sasaki J, Branch C, Roth JA and
Mukhopadhyay T: 5-aza-2′-deoxycytidine upregulates caspase-9
expression cooperating with p53-induced apoptosis in human lung
cancer cells. Oncogene. 23:6779–6787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inman BA, Stauffer PR, Craciunescu OA,
Maccarini PF, Dewhirst MW and Vujaskovic Z: A pilot clinical trial
of intravesical mitomycin-C and external deep pelvic hyperthermia
for non-muscle-invasive bladder cancer. Int J Hyperthermia.
30:171–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rosenberg SA and Restifo NP: Adoptive cell
transfer as personalized immunotherapy for human cancer. Science.
348:62–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maus MV, Fraietta JA, Levine BL, Kalos M,
Zhao Y and June CH: Adoptive immunotherapy for cancer or viruses.
Annu Rev Immunol. 32:189–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inamura SO, Ito H, Taga M, Tsuchiyama K,
Hoshino H, Kobayashi M and Yokoyama O: Low-dose docetaxel enhanced
the anticancer effect of temsirolimus by overcoming autophagy in
prostate cancer cells. Anticancer Res. 39:5417–5425. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Q, Tian K, Xu J, Zhang H, Li L, Fu
Q, Chai D, Li H and Zheng J: Synergistic effects of cabozantinib
and EGFR-Specific CAR-NK-92 cells in renal cell carcinoma. J
Immunol Res. 2017:69159122017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang Y, Tang Y and Cheng YS: MiR-34a
inhibits pancreatic cancer progression through Snail1-mediated
epithelial–mesenchymal transition and the Notch signaling pathway.
Sci Rep. 7:382322017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zitvogel L, Apetoh L, Ghiringhelli F and
Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev
Immunol. 8:59–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mbeunkui F and Johann DJ Jr: Cancer and
the tumor microenvironment: A review of an essential relationship.
Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo XH, Ni J, Xue JL and Wang X:
Phyllanthus emblica Linn. fruit extract potentiates the anticancer
efficacy of mitomycin C and cisplatin and reduces their
genotoxicity to normal cells in vitro. J Zhejiang Univ Sci B.
18:1031–1045. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye LY, Hu S, Xu HE, Xu RR, Kong H, Zeng
XN, Xie WP and Wang H: The effect of tetrandrine combined with
cisplatin on proliferation and apoptosis of A549/DDP cells and A549
cells. Cancer Cell Int. 17:402017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang X, Chen YT, Song HZ, Huang GC and
Chen LB: Cisplatin pretreatment enhances anti-tumor activity of
cytokine-induced killer cells. World J Gastroenterol. 17:3002–3011.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bergmann-Leitner ES and Abrams SI:
Treatment of human colon carcinoma cell lines with anti-neoplastic
agents enhances their lytic sensitivity to antigen-specific CD8+
cytotoxic T lymphocytes. Cancer Immunol Immunother. 50:445–455.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vollebergh MA, Kappers I, Klomp HM,
Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den
Heuvel MM and Linn SC: Ligands of epidermal growth factor receptor
and the insulin-like growth factor family as serum biomarkers for
response to epidermal growth factor receptor inhibitors in patients
with advanced non-small cell lung cancer. J Thorac Oncol.
5:1939–1948. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heuer JG, Harlan SM, Yang DD, Jaqua DL,
Boyles JS, Wilson JM, Heinz-Taheny KM, Sullivan JM, Wei T, Qian HR,
et al: Role of TGF-alpha in the progression of diabetic kidney
disease. Am J Physiol Renal Physiol. 312:F951–F962. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nowak AK, Lake RA, Marzo AL, Scott B,
Heath WR, Collins EJ, Frelinger JA and Robinson BW: Induction of
tumor cell apoptosis in vivo increases tumor antigen
cross-presentation, cross-priming rather than cross-tolerizing host
tumor-specific CD8 T cells. J Immunol. 170:4905–4913. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang X, Guan D, Shu YQ, Liu LK and Ni F:
Effect of cisplatin on the frequency and immuno-inhibitory function
of myeloid-derived suppressor cells in a375 melanoma model. Asian
Pac J Cancer Prev. 16:4329–4333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu J, Zhong Y, Peng S, Zhou X and Gan X:
Efficacy and safety of PD1/PDL1 blockades versus docetaxel in
patients with pretreated advanced non-small-cell lung cancer: A
meta-analysis. Onco Targets Ther. 11:8623–8632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan TSY, Li J, Loong F, Khong PL, Tse E
and Kwong YL: PD1 blockade with low-dose nivolumab in NK/T cell
lymphoma failing L-asparaginase: Efficacy and safety. Ann Hematol.
97:193–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roybal KT, Rupp LJ, Morsut L, Walker WJ,
McNally KA, Park JS and Lim WA: Precision tumor recognition by T
cells with combinatorial antigen-sensing circuits. Cell.
164:770–779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jackson HJ, Rafiq S and Brentjens RJ:
Driving CAR T-cells forward. Nat Rev Clin Oncol. 13:370–383. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang J, Wahdan-Alaswad R and Danielpour D:
Critical role of Smad2 in tumor suppression and transforming growth
factor-beta-induced apoptosis of prostate epithelial cells. Cancer
Res. 69:2185–2190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
di Bari MG, Lutsiak ME, Takai S, Mostböck
S, Farsaci B, Semnani RT, Wakefield LM, Schlom J and Sabzevari H:
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T
cells through effects on TCR signaling and Spred1 expression.
Cancer Immunol Immunother. 58:1809–1818. 2009. View Article : Google Scholar : PubMed/NCBI
|
